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Data to better understand and manage the COVID-19 pandemic is urgently needed. How-
ever, there are gaps in information stored within even the best routinely-collected electronic
health records (EHR) including test results, remote consultations for suspected COVID-19,
shielding, physical activity, mental health, and undiagnosed or untested COVID-19 patients.
Observational and Pragmatic Research Institute (OPRI) Singapore and Optimum Patient
Care (OPC) UK established Platform C19, a research database combining EHR data and
bespoke patient questionnaire. We describe the demographics, clinical characteristics,
patient behavior, and impact of the COVID-19 pandemic using data within Platform C19.
Methods
EHR data from Platform C19 were extracted from 14 practices across UK participating in
the OPC COVID-19 Quality Improvement program on a continuous, monthly basis. Starting
7th August 2020, consenting patients aged 18–85 years were invited in waves to fill an online
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questionnaire. Descriptive statistics were summarized using all data available up to 22nd
January 2021.
Findings
From 129,978 invitees, 31,033 responded. Respondents were predominantly female
(59.6%), white (93.5%), and current or ex-smokers (52.6%). Testing for COVID-19 was
received by 23.8% of respondents, of which 7.9% received positive results. COVID-19
symptoms lasted�4 weeks in 19.5% of COVID-19 positive respondents. Up to 39% respon-
dents reported a negative impact on questions regarding their mental health. Most (67%-
76%) respondents with asthma, Chronic Obstructive Pulmonary Disease (COPD), diabetes,
heart, or kidney disease reported no change in the condition of their diseases.
Interpretation
Platform C19 will enable research on key questions relating to COVID-19 pandemic not pos-
sible using EHR data alone.
Introduction
The COVID-19 pandemic added further burden on already stretched healthcare systems,
including the routine management of patients with chronic diseases [1–4]. Primary care prac-
titioners are especially affected as the pandemic limits their access to information regarding
the health status of their patients (1).
Due to the pandemic emergency arrangements, important information gaps and inconsis-
tencies emerged within electronic health records (EHR). Such gaps include the initial lack of
codes for tests, diagnosis, and symptoms test results, remote consultations with NHS111 tele-
phone service (the UK non-emergency medical care hotline), hospital consultations, as well as
self-treatment or home testing. To understand the COVID-19-vulnerable population and clin-
ical outcomes, key information is required on co-morbidities, medication and patient behavior
such as shielding, isolation, and health-seeking behavior, information on mental health, and
status of pre-existing chronic diseases.
In response to the pandemic, Observational and Pragmatic Research Institute (OPRI) Sin-
gapore and OPC (Optimum Patient Care) UK established the COVID-19 Quality Improve-
ment (QI) program (https://optimumpatientcare.org/covid-qi/). QI programs refer to
systematic sets of actions conducted to improve the quality of patient care [5, 6]. The COVID-
19 QI program aims to assist primary care in assessing the incidence and impact of COVID-19
and to identify patients at-risk for COVID-19 or with suggestive symptoms who are in need of
help [7]. The COVID-19 QI program also aims to increase our understanding of the pandemic
such as the risk predictors of long COVID [8], the impact of the pandemic on other chronic
diseases, and other potential impacts of the pandemic not yet known due to reduced healthcare
consultation during the pandemic. These will be achieved by the generation of patient and
practice level quality improvement reports containing key patient information combining de-
identified electronic health data and patient questionnaire responses to participating practices.
Using data collected as part of this QI program, OPC established Platform C19 (https://
opcrd.co.uk/platform-c19-new-2/) on September 23, 2020. Platform C19 is a novel primary
care, patient-centered research platform supported by a multi-organizational research
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collaboration. The platform incorporates both EHR data and patient self-reported question-
naire results thereby providing a unique and comprehensive data source to facilitate multiface-
ted research into the COVID-19 pandemic [9].
The current article describes the development of the platform, the data collected within the
platform C19, and summarizes the demographics, clinical characteristics, and behavioral pat-
terns of the patients from the first wave of the pandemic. The impact of the pandemic on self-




This paper describes an observational, descriptive analysis of data stored in Platform C19 col-
lected from 7th August 2020 up till 22nd January 2021. The analysis includes both EHR data
and patient-reported information collected via questionnaire contained within Platform C19.
Development of the platform and data collection
The OPC possesses an established track record and technical expertise in maintaining large
scale research databases. We maintain the Optimum Patient Care Research Database
(OPCRD), an anonymized, quality-controlled, longitudinal primary care database integrating
records for more than 12 million patients from over 800 GP practices across the UK supple-
mented with linked patient reported outcome data from over 70 thousand patients (https://
opcrd.co.uk/our-database/). Bringing our expertise, we established Platform C19 deriving
EHR data from the OPCRD. OPC quality improvement programs are provided in compliance
with the General Data Protection Regulation (GDPR)/Data Protection Act 2018 (Data Protec-
tion Register Ref: ZA197058) and the NHS Data Security and Protection Toolkit (Ref: 8HR85).
The OPCRD has received NHS research ethics committee (REC) approval to provide anon-
ymized data for scientific and medical research since 2010, with its most recent approval in
2015 (NHS HRA REC ref: 15/EM/0150). OPCRD is governed by the Anonymized Data Ethics
and Protocols Transparency (ADEPT) committee (ADEPT1720), and the protocol of Platform
C19 was approved by the ADEPT committee on 18th November 2020. The OPCRD routinely
receives de-identified EHR data from GPs participating in OPC QI programs.
Access to the deidentified patient data used in this study may be requested via the OPCRD
website (https://opcrd.co.uk/platform-c19-new-2/) or via the enquiries email info@opcrd.co.
uk.
All patients aged 18–85 years old at the start of the pandemic (1stMarch 2020) registered
within practices participating in the COVID-19 QI program were invited in waves to complete
an online COVID-19 questionnaire via text-message from their practice starting from 7th
August 2020. The questionnaire was designed by an expert consensus from the Platform C19
steering committee. The questionnaire covers the patient demographics, COVID-19 symp-
toms, diagnosis, and testing, pandemic related behavior, mental health, chronic health condi-
tions, and detailed questions relating to asthma and COPD. The current version of the
questionnaire is provided in the supplementary material. Every patient has a unique link that
is attached to the electronic medical record and patient ID. This unique patient link can only
be unlocked within the originating practice site. The questionnaire is sent to the patients via
the medical record system of the participating practices. Responses are automatically recorded
and linked to the patient ID.
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Data is securely stored in an enterprise database running SQL-Server (Windows Server
2019 Standard (10.0) Version 15.0.2080.9). The list of variables collected within the platform
and the sources are available in the online supplementary material (S1 Table).
To prepare data for analysis, questionnaire responses and relevant electronic medical rec-
ords were collated, cleaned, and then summarized. If a patient had responded to more than
one round of questionnaires, only the most recent response was used to include the most
updated patient status into the analysis. This analysis includes patients who had responded to
the COVID-19 questionnaire. Patients who opt-out from data-sharing for research [10] are
excluded.
Study variables
De-identified electronic health record (EHR) data and patient-reported COVID-19 question-
naire results were used in this study. Variables derived from the EHR include sex, age, frailty,
and smoking status. Variables supplemented from patient-reported data include ethnicity, Body
Mass Index (BMI), COVID-19 status, patient behavior, mental health status, and status of under-
lying chronic diseases. Asthma and COPD exacerbation were defined as requiring a course of at
least 3 days of oral corticosteroid due to worsening of the condition. Respondents were consid-
ered to have had long COVID if they report symptoms lasting at least 4 weeks [11–14].
Statistical analysis
Descriptive statistics were computed for all demographic and clinical variables using all avail-
able patient data. Categorical variables were presented as numbers and percentages. Percent-
ages are presented according to the number of patients who answered the questions relevant
to each specific variable.
Results
Response summary
A total of 129,978 questionnaire invitations were sent to all eligible patients from 14 participat-
ing general practices. Of these, 31,033 (23.9%) responded to the questionnaire (Fig 1). The
average time between responses and the start of the pandemic (1st March 2020) was 31.8
weeks. The average Index of Multiple Deprivation of participating practices was close to the
national average with slight skew to the deprived (13231.38) and good coverage of all regions
across England.
Patient demographics and characteristics
The demographics and characteristics of the respondents are summarized in Table 1. The
majority of the responding patients were female (18,504/31,033; 59.6%). Nearly all respondents
were white (British, Irish, other [23,929/25,591; 93.5%]). Almost half (13,681/31,033; 44.1%)
were above 60 years while 18.0% were between 18–40 years. Smoking history was common
with 3,535/31,033 (11.4%) respondents reporting currently smoking and 12,792/31,033
(41.2%) previously smoking. A large proportion was also either overweight (BMI between 25.0
and 29.9 [9,966/31,033; 32.1%]) or obese (BMI>30�0 [10,945/31,033; 35.2%]). Frailty was
present in 1,065/31,033 (3.4%) respondents.
COVID-19 status
Testing for COVID-19 was conducted on 7,051/29,599 (23.8%) respondents, of which 543/
6,904 (7.9%) reported positive test results (Fig 1). Of these, 65/543 (12.0%) were received by
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Fig 1. Patient flow.
https://doi.org/10.1371/journal.pone.0258689.g001
PLOS ONE Patient characteristics in platform C19, a COVID-19 research database
PLOSONE | https://doi.org/10.1371/journal.pone.0258689 October 19, 2021 5 / 13
patients who did not have symptoms since January 2020. Long COVID, symptoms lasting 4 or
more weeks, was reported by 106/543 (19.5%) positive test respondents. Further, 71/543
(13.1%) reported symptoms lasting beyond 12 weeks. More than half (362/543; 66.7%), did not
seek medical attention from their GP or hospital for COVID-19 infection or symptoms. Only
120/543 (22.1%) contacted NHS 111. Around one-fifth (108/543; 19.9%) contacted their GP,
of which 19/108 (17.6%) were face-to-face consultations.
Table 1. Demographic and clinical characteristics of survey respondents (n = 31,033).
Baseline characteristics N (%)a
Sex •Male 12,528 (40�4%)
• Female 18,504 (59�6%)
Age group • 18 - <40 5,572 (18�0%)
• 40 - <50 4,608 (14�8%)
• 50 - <60 7,172 (23�1%)
• 60 - <70 7,408 (23�9%)
• 70 - <80 5,348 (17�2%)
• 80+ 925 (3�0%)
Body mass index • <18�5 397 (1�3%)
• 18�5–24�9 7,794 (25.1%)
• 25–29�9 9,966 (32.1%)
• 30–39�9 8,949 (28.8%)
• �40 1,996 (6�4%)
Race •White (British, Irish, other) 23,929 (93�5%)
• Asian / Asian British 805 (2�6%)
• Black / Black British 187 (0�6%)
•Mixed race—White and Black/Black British 86 (0�3%)
•Mixed race—Chinese / Chinese British 96 (0�3%)
•Mixed race—Hispanic or Latino or Spanish origin 74 (0�2%)
•Mixed race—Middle Eastern / Middle Eastern British 61 (0�2%)
•Mixed race–other 147 (0�5%)
• Others 270 (0�9%)
Smoking status • Current smokers 3,535 (11�4%)
• Ex-smokers 12,792 (41�2�%)
• Non-smokers 14,094 (45�4%)
Shielding during the pandemic • Shielded 1,984 (6�8%)
• Not shielded 27,203 (93�2%)
Frailty • No reported frailty 29,968 (96�6%)
• Reported frailty 1,065 (3�4%)
Chronic co-morbid conditions • Question response rate 27,149 (87�5%)
• Any condition 7,638 (28�1%)
• Asthma 3,755 (13�8%)
• COPD, bronchitis, emphysema 1,053 (3�9%)
• Diabetes 2,358 (8�7%)
•Heart disease or heart failure 1,585 (5�8%)
• Kidney disease 463 (1�7%)
aPercentages are based on the total number of known responses.
https://doi.org/10.1371/journal.pone.0258689.t001
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Behavior and mental health
Advice letters to shield during the pandemic was received by 2,234/29,186 (7.7%) respondents,
of which 1,984/2,234 (88.8%) reported to have been shielding. A total of 1,935/27,396 (7.1%)
respondents were asked to remain home for at least 14 days after travel or exposure to
COVID-19. Since March 2020, most respondents reported a decrease in the frequency they
interacted with family and friends (23,828 /26,992; 88.3%) or left their houses (20,503/26,723;
77.4%). No change, decrease, and increase in the frequency they contacted their doctors were
reported by 15,368/26,747 (57.5%), 9,901/26,747 (37.0%) and 1,478/26,747 (5.5%) respondents
respectively. While 9,094/26,181 (34.7%) reported a decrease in physical activity, another
6,250/26,181 (23.9%) reported an increase in physical activity during the pandemic (Fig 2).
Up to 39% of respondents reported negative impact on question relating to their mental
health status in the past 2 weeks (Fig 3). Feeling of nervousness, anxiousness, or on-edge was
the most commonly reported (10,789/27,581; 39.1%) mental health problem.
Chronic diseases status
Chronic conditions of asthma, COPD, diabetes, heart failure, and kidney disease were reported
by 3,755/27,149 (13.8%), 1,053/27,149 (3.9%), 2,358/27,149 (8.7%), 1,585/27,149 (5.8%), and
463/27,149 (1.7%) patients respectively (Table 1). Most (67–76%) respondents reported no
change in the conditions of their diseases since March 2020 (Fig 4).
Most patients with asthma and/or COPD reported not having experienced any exacerba-
tion in the past 12 months (3,162/4,185; 75.6%). Only a small proportion reported having been
hospitalized (175/4,156; 4.2%) or treated in an emergency department (272/4,186; 6.5%) due
to the worsening of their conditions (Fig 5).
Discussion
Summary of findings
In the current article, we describe the patient characteristics available within Platform C19.
Platform C19 is a large population-based platform linking patient reported data linked to
Fig 2. Change in respondents’ activity since March 2020.
https://doi.org/10.1371/journal.pone.0258689.g002
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electronic medical records. The platform combines OPCRD’s unique access to anonymized
EHR data with patient-reported information, providing additional insight on data that are not
usually collected during routine clinical visits. These include data on patient behavior, poten-
tially missed COVID-19 patients, changes in physical activity, and mental health. The platform
Fig 3. Responses to questions on mental health status in the past 2 weeks.
https://doi.org/10.1371/journal.pone.0258689.g003
Fig 4. Patient-reported change in chronic conditions status since March 2020.
https://doi.org/10.1371/journal.pone.0258689.g004
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thus provides a unique data source to answer important research questions on the COVID-19
pandemic which cannot be answered using only routine primary care EHR data.
Only a quarter of the respondents reported having been tested for COVID-19. The propor-
tion of respondents who reported positive test results (8%) was observed to be slightly higher
than the UK national data as of 22nd January 2021 (56%, https://coronavirus.data.gov.uk/).
Additionally, more than half reported not having sought medical attention for their COVID-
19 infection or symptoms, This might have stemmed from patient reluctance to seek medical
attention when they have only mild complaints. These imply that some COVID-19 cases will
not be identified in EHRs.
Respondents mostly reported decreases in the frequency of interaction with family or
friends and the frequency of leaving their houses since the pandemic. However, 42% and 24%
of respondents reported no change or an increase in physical activities respectively despite the
pandemic. This is consistent with a previous study by Spence et al that reported the majority
(57%) of 1,521 adults in the UK responded to have either maintained or increased their physi-
cal activities level during the lockdown [15]. Despite this, the authors also report that the pro-
portion of respondents who did not meet guideline recommended levels of physical activity
increased during the pandemic.
Studies have consistently reported the impact of the pandemic on population mental health
[16–18]. This is similarly observed among our respondents as around one-third reported some
degree of negative impact in the questions regarding mental health. This observation implies a
major impact of the pandemic which reaches beyond physical disturbances and highlights a
need for public health policies to assist the population especially the vulnerable [19].
The pandemic disrupted the delivery of routine primary care including patients with
chronic diseases [3]. However, the majority of the respondents reported no change to the sta-
tus of their chronic disorders during the pandemic. Most respondents with asthma and/or
COPD also reported that their symptoms had been well-controlled in the past year. These
Fig 5. Prevalence of patient-reported markers of exacerbation of asthma and/or COPD in the past 12 months.
https://doi.org/10.1371/journal.pone.0258689.g005
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findings suggest that the majority of patients with chronic diseases may not have required
face-to-face consultation with their general practitioners during the first wave of the pandemic
and suggests that use of remote methods such as text message generated questionnaires or tele-
phone reviews could support monitoring of chronic diseases including asthma and COPD.
Further studies using data in the C19 Platform
Platform C19 is an open platform designed to facilitate collaboration and sharing of research
data and resources. OPC invites collaborators to conduct crucial research on COVID-19 using
the breadth of data stored in the platform.
Potential research includes analysis of the gaps in EHR recorded COVID-19 compared to
the self-suspected COVID-19. Analyses of patients with self-suspected COVID-19 infection
are hoped to shed information on this patient group.
Patients with chronic diseases may choose to shield during this period, which may then
negatively impact their activity and quality of life [20]. Previous studies have also reported
reduction in asthma and COPD related health visits since the start of the pandemic in the UK
[21–23]. Whether this is due to real reductions in asthma and COPD exacerbations or due to
changes in health-seeking behavior warrants further investigations. Future studies using the
platform will therefore analyze the impact of shielding and other patient behavioral patterns
during the pandemic towards the outcome of pre-existing chronic diseases such as asthma and
COPD. Conversely, further studies will also investigate the influence of pre-existing chronic
diseases on patient behavior and COVID-19 infection risk and outcome. The impact of the
lockdown on the well-being of at-risk patients such as the frail, elderly, and those with multiple
co-morbidities also needs to be elucidated.
Currently, there are gaps in our knowledge regarding symptoms of COVID-19 which per-
sists after the infection, a phenomenon termed” long COVID” [24–26]. A deeper study into
the subgroup of patients with long COVID identified within Platform C19 is therefore war-
ranted to identify the potential risk factors for long COVID. This will include investigation
into whether patients who self-suspected and self-managed their COVID-19 symptoms subse-
quently develop long COVID.
Platform C19 aims to continue data collection in the next 12 months and we expect a dou-
bling in the number of data collected by April 2021. As the pandemic evolves, continued data
collection will allow long-term follow up of patients with COVID-19. This will enable research
on the impacts of new variants of the virus and the effectiveness of vaccination and other inter-
ventions including lockdowns and self-isolation.
Future rounds of questionnaire may aim to collect additional information on lockdown
deconditioning (weakening of muscles due to decrease in physical activities during the lock-
down), healthcare avoidance, and the impact of vaccination of their physical and mental health
while subsequently increasing the representation of the Black, Asian, and minority ethnic
patients within the platform. Such information will be valuable to provide recommendations
for public health practitioners during a global pandemic. Platform C19 will also aim for the
opportunity to link its data with secondary care data.
Conclusions
Platform C19 is a unique research database which supplements routine EHR data with
patient-reported information and outcome such as isolation behavior, mental health, and
health-seeking behavior. This dataset enables researchers to answer key research questions on
the pandemic which cannot be answered from routinely collected EHR data alone. We cur-
rently observe that majority of patients with chronic disease had their symptoms controlled.
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Respondents also reported some degree of impact on their activity and mental health due to
the pandemic. Future studies conducted using Platform C19 will seek to better our under-
standing of the relationship between co-morbid chronic diseases, patient behavior, and
COVID-19 outcome as the pandemic evolves.
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